Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. Its products include Emergen, Foramin, Foramin ST, Pacesetter, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which are bio fungicides that protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. The company provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Davis, California.
IPO Year: 2013
Exchange: NASDAQ
Website: marronebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2021 | $2.00 | Buy | Roth Capital |
| 8/19/2021 | $3.50 → $2.50 | Buy | Aegis Capital |
Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously
Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50
Canaccord Genuity reiterated coverage of Marrone Bio Innovations with a rating of and set a new price target of $3.50 from $2.00 previously
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50 from $1.65 previously
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced
DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and inves
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
ROTH MKM ("Roth"), www.roth.com, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors. ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (NASDAQ:MBII) ("MBI"). "The completion of this transaction represents an important milestone in our journey, cementing our leadership in the development and commercialization of sustainable agricultural solutions," said Bioceres Chief Executive Officer, Federico Trucco. "MBI brings 15 years of experience in the development of biological solutions, and we are excited to a
RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by t
RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material
RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m
RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So
RALEIGH, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), has signed an agreement with Corteva Agriscience (NYSE:CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. MBI introduced biological seed treatments as a sustainable alternative to control yield-robbing pests in the United States in 2017. Those offerings expanded to include plant health solutions, particularly in the European market, with the acquisition of Pro Farm in 2019. Today, more than 30% of MBI's annual revenues come from seed techn
Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible notes into shares and new term loan facility Bioceres Crop Solutions Corp. (NASDAQ:BIOX) (Bioceres) and Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. Under the terms of the transaction, which has been unanimously approved by the Board of Directors of both companies, each share of MBI common stock will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088, repres
Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible notes into shares and new term loan facility ROSARIO, Argentina and RALEIGH, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Bioceres Crop Solutions Corp. (NASDAQ:BIOX) (Bioceres) and Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. Under the terms of the transaction, which has been unanimously approved by the Board of Directors of both companies, each share of MBI common stock will be exchanged at
RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2021, after market close on Monday, March 28, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' fourth quarter and full year 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q4 2021 Conference Call and Webcast Date:
15-12G - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material
RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m
RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So
Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible notes into shares and new term loan facility Bioceres Crop Solutions Corp. (NASDAQ:BIOX) (Bioceres) and Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. Under the terms of the transaction, which has been unanimously approved by the Board of Directors of both companies, each share of MBI common stock will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088, repres
Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible notes into shares and new term loan facility ROSARIO, Argentina and RALEIGH, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Bioceres Crop Solutions Corp. (NASDAQ:BIOX) (Bioceres) and Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. Under the terms of the transaction, which has been unanimously approved by the Board of Directors of both companies, each share of MBI common stock will be exchanged at
RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2021, after market close on Monday, March 28, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' fourth quarter and full year 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q4 2021 Conference Call and Webcast Date:
DAVIS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021. Key results include: Strategic focus on global expansion in the major row crops was a key contributor to the 12% revenue growth for the third quarter. Sales of biological fungicides also increased during the period.Stronger mix of higher margin seed treatments led to gross profit of 61.4% in the third quarter, the 12th consecutive quarter of gross margins in excess of 50%.The net loss in the third quarter of 2021 was $4.9 million, as c
DAVIS, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the third quarter ended September 30, 2021, after market close on Wednesday, November 10, 2021 at 4:30 p.m. Eastern time. Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) on November 10, 2021 to discuss Marrone Bio Innovations' third quarter 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q3 2
DAVIS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the second quarter ended June 30, 2021. Key results include: The net loss in the second quarter was $3 million, a 6% increase, and Adjusted EBITDA was a loss of $0.7 million, a 51% improvement. For the first half of 2021, net income (loss) and Adjusted EBITDA improved 36% and 63%, respectively.Second quarter revenues rose 3%, with growth in specialty and row crop products constrained by challenging weather and supply chain conditions.Gross profit in the second qu